Transactivation by AP-1 is a molecular target of T cell clonal anergy
SM Kang, B Beverly, AC Tran, K Brorson, RH Schwartz… - Science, 1992 - science.org
Anergy is a mechanism of T lymphocyte tolerance induced by antigen receptor stimulation
in the absence of co-stimulation. Anergic T cells were shown to have a defect in antigen-…
in the absence of co-stimulation. Anergic T cells were shown to have a defect in antigen-…
Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins
K Brorson, S Krejci, K Lee, E Hamilton… - Biotechnology and …, 2003 - Wiley Online Library
Viral safety is a predominant concern for monoclonal antibodies (mAbs) and other recombinant
proteins (RPs) with pharmaceutical applications. Certain commercial purification modules…
proteins (RPs) with pharmaceutical applications. Certain commercial purification modules…
N-glycosylation design and control of therapeutic monoclonal antibodies
The N-linked glycan profiles on recombinant monoclonal antibody therapeutics significantly
affect antibody biological functions and are largely determined by host cell genotypes and …
affect antibody biological functions and are largely determined by host cell genotypes and …
The current scientific and regulatory landscape in advancing integrated continuous biopharmaceutical manufacturing
AC Fisher, MH Kamga, C Agarabi, K Brorson… - Trends in …, 2019 - cell.com
There is a trend across the pharmaceutical sector toward process intensification and
continuous manufacturing to produce small-molecule drugs or biotechnology products. For …
continuous manufacturing to produce small-molecule drugs or biotechnology products. For …
Analysis of viral clearance unit operations for monoclonal antibodies
G Miesegaes, S Lute, K Brorson - Biotechnology and …, 2010 - Wiley Online Library
Demonstration of viral clearance is a critical step in assuring the safety of biotechnology
products. We generated a viral clearance database that contains product information, unit …
products. We generated a viral clearance database that contains product information, unit …
Mutational analysis of avidity and fine specificity of anti-levan antibodies
K Brorson, C Thompson, G Wei… - The Journal of …, 1999 - journals.aai.org
Using the polyfructose, bacterial levan, as a model polysaccharide, we analyzed how V regions
affect binding in anti-polysaccharide mAbs. Previously, panels of mAb were constructed …
affect binding in anti-polysaccharide mAbs. Previously, panels of mAb were constructed …
Normal‐flow virus filtration: Detection and assessment of the endpoint in bioprocessing
…, M Rubino, S Lute, K Brorson… - Biotechnology and …, 2005 - Wiley Online Library
The breakthrough of a model virus, bacteriophage ΦX‐174, through normal‐flow virus filters
was studied using both commercial process fluids and model feedstreams. The results …
was studied using both commercial process fluids and model feedstreams. The results …
Mycoplasma testing of cell substrates and biologics: review of alternative non-microbiological techniques
DV Volokhov, LJ Graham, KA Brorson… - Molecular and cellular …, 2011 - Elsevier
Mycoplasmas, particularly species of the genera Mycoplasma and Acholeplasma, are
known to be occasional microbial contaminants of cell cultures that produce biologics. This …
known to be occasional microbial contaminants of cell cultures that produce biologics. This …
Validation of an optical sensor-based high-throughput bioreactor system for mammalian cell culture
X Ge, M Hanson, H Shen, Y Kostov, KA Brorson… - Journal of …, 2006 - Elsevier
Cell culture optimization is a labor-intensive process requiring a large number of experiments
to be conducted under varying conditions. Here we describe a high-throughput bioreactor …
to be conducted under varying conditions. Here we describe a high-throughput bioreactor …
Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow‐through mode
S Curtis, K Lee, GS Blank, K Brorson… - Biotechnology and …, 2003 - Wiley Online Library
The potential of viral contamination is a regulatory concern for continuous cell line‐derived
pharmaceutical proteins. Complementary and redundant safety steps, including an …
pharmaceutical proteins. Complementary and redundant safety steps, including an …